Catalyst Dossier · compiled by CeliA 🧫

Y-mAbs Therapeutics, Inc. (YMAB)

Pharmaceutical Preparations · market cap $391M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Y-mAbs Therapeutics (YMAB) is a commercial-stage pharma focused on antibody-based therapies, with its lead asset being GM-CSF combined with naxitamab in Phase 2 for neuroblastoma. The company reported $88M in 2024 revenue against a $30M net loss, suggesting a product already generating meaningful sales. At a $391M market cap and ~$8.61/share, the stock trades at roughly 4.4x trailing revenue with no analyst coverage and no near-term catalysts on the calendar.

The catalyst path

2026-12-15 (est.)Phase 2 · Hu3F8 With GM-CSFimp 7/10
2027-07-15 (est.)Phase 2 · humanized anti-GD2 antibodyimp 7/10
2027-07-15 (est.)Phase 2 · 131 I-omburtamabimp 7/10

Pipeline

Asset	Phase	Indication
GM-CSF + Naxitamab	Phase 2	Neuroblastoma
Hu3F8 With GM-CSF	Phase 2	Neuroblastoma
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH	Phase 2	Neuroblastoma
Hu3F8	Phase 2	Neuroblastoma
Naxitamab	Phase 2	Neuroblastoma
131 I-omburtamab	Phase 2	Desmoplastic Small Round Cell Tumor
humanized anti-GD2 antibody	Phase 2	Recurrent Osteosarcoma
Omburtamab I-131	Phase 2	Recurrent Medulloblastoma

Price & technical context

3-month

+82.8%

6-month

+84.4%

12-month

-35.1%

52-wk range

$3.64–$15.69

vs 50-day MA

+25.8%

vs 200-day MA

+40.7%

Realized vol

95.3%

Max drawdown

-80.5%

Daily closes through 2025-09-15. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for YMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.